Literature DB >> 1155926

In vitro susceptibility of Pseudomanas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole.

M R Moody, W M Young.   

Abstract

Our earlier studies had shown that the two pseudomonads, Pseudomonas cepacia and Pseudomonas maltophilia, were organisms that were highly resistant to most antibiotics. The present study was undertaken to determine the susceptibility of these bacteria to trimethoprim and the trimethoprim-sulfamethoxazole combination which has been used with apparent success in treating infections caused by these pseudomonads. All 51 strains of P. cepacia were inhibited by 2 mug or less of trimethoprim per ml, whereas all 45 of the P. maltophilia were resistant to greater than 32 mug/ml. When the P. maltophilia was tested against trimethoprim-sulfamethoxazole, two strains were resistant and one only moderately resistant, but all other strains were susceptible. All P. cepacia strains were also susceptible with an average zone of inhibition significantly larger than for P. maltophilia (P < 0.005). These in vitro studies support recent case study reports of successful therapy using the trimethoprim-sulfamethoxazole combination.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155926      PMCID: PMC429236          DOI: 10.1128/AAC.7.6.836

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pseudomonas cepacia (multivorans) septicaemia in an intensive-care unit.

Authors:  I Phillips; S Eykyn; M A Curtis; J J Snell
Journal:  Lancet       Date:  1971-02-20       Impact factor: 79.321

2.  Wound infection with Pseudomonas multivorans. A water-borne contaminant of disinfectant solutions.

Authors:  D C Bassett; K J Stokes; W R Thomas
Journal:  Lancet       Date:  1970-06-06       Impact factor: 79.321

3.  Successful treatment of Pseudomonas cepacia endocarditis in a heroin addict with trimethoprim-sulfamethoxazole.

Authors:  H C Neu; G J Garvey; M P Beach
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  Infrequently encountered Pseudomonas species causing infection in humans.

Authors:  G L Gilardi
Journal:  Ann Intern Med       Date:  1972-08       Impact factor: 25.391

5.  Colonization and infection with Pseudomonas cepacia.

Authors:  G M Ederer; J M Matsen
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

6.  Characterization of saccharolytic nonfermentative bacteria associated with man.

Authors:  M J Pickett; M M Pedersen
Journal:  Can J Microbiol       Date:  1970-05       Impact factor: 2.419

7.  Nonfermentative gram-negative bacilli of nosocomial interest.

Authors:  P Gardner; W B Griffin; M N Swartz; L J Kunz
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

8.  Characterization of EO-1 strains (Pseudomonas kingii) isolated from clinical specimens and the hospital environment.

Authors:  G L Gilardi
Journal:  Appl Microbiol       Date:  1970-09

9.  Pseudomonas cepacia from blood of a burn patient.

Authors:  E Yabuuchi; N Miyajima; H Hotta; A Oyama; N Tanaka
Journal:  Med J Osaka Univ       Date:  1970-12

10.  In vitro antibiotic susceptibility of pseudomonads other than Pseudomonas aeruginosa recovered from cancer patients.

Authors:  M R Moody; V M Young; D M Kenton
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

View more
  10 in total

1.  Pseudomonas cepacia susceptibility to sulbactam.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 4.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

7.  Fourteen-year survival of Pseudomonas cepacia in a salts solution preserved with benzalkonium chloride.

Authors:  S G Geftic; H Heymann; F W Adair
Journal:  Appl Environ Microbiol       Date:  1979-03       Impact factor: 4.792

8.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Septic arthritis caused by treatment resistant Pseudomonas cepacia.

Authors:  E L Matteson; W J McCune
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

Review 10.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.